(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA), and Alvotech (ALVO) on Friday announced the availability of Selarsdi or ustekinumab-aekn injection, a biosimilar to Stelara or ustekinumab in the U.S. market.
This marks the second biosimilar developed under their strategic partnership and is approved for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn's disease, and ulcerative colitis in both adults and pediatric patients of six years and older.
Tel Aviv, Israel - based Teva and Luxembourg-based Alvotech has been into a strategic partnership since 2020, for commercialization of five Alvotech biosimilar product candidates.
The U.S. Food and Drug Administration has provisionally determined that Selarsdi will be interchangeable with Stelara once exclusivity for the first interchangeable biosimilar expires on April 30, 2025.
Selarsdi is approved in several presentations and is designed to help lower healthcare costs, providing more affordable treatment options for patients in the U.S.
This milestone supports the companies' ongoing collaboration to expand access to high-quality biologics and biosimilars in the market.
TEVA closed Thursday's (Feb.20 2025) trading at $17.00 down by 0.93%. In premarket trading Friday the stock is up by 2.00% at $17.34.
AVO closed Thursday's (Feb.20 2025) trading at $11.70 down by 0.17%. In premarket trading Friday the stock is up by 2.99% at $12.05.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
